Skip to content
TrialScanner

NCT04684940

Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

Phase 1/Phase 2CompletedBMRNLead

Registry record

Lead sponsor
BioMarin Pharmaceutical
Conditions
Hemophilia A With Inhibitor; Hemophilia A With Anti Factor VIII
Primary completion
Apr 20, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04684940 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04684940: Safety, Tolerability, and... | TrialScanner